Summary & Overview
HCPCS J1060: Testosterone Cypionate and Estradiol Cypionate Injection
HCPCS Level II code J1060 denotes an injectable combination of testosterone cypionate and estradiol cypionate (up to 1 ml). This code identifies a combined hormone therapy product administered by injection and is relevant for clinicians, payers, and billing professionals managing hormone replacement or related therapeutic regimens. Nationally, accurate use of this HCPCS code matters for correct claims adjudication, inventory tracking, and consistent reporting of combined hormone injections.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings, benchmarking and coverage considerations where available, and notes on billing practice implications tied to a combined androgen-estrogen injectable product. The publication summarizes coding intent, typical sites of service, and the practical implications for claims processing and documentation. Data not available in the input are noted where applicable. The content is presented to support coding accuracy and administrative clarity around HCPCS Level II code J1060.
Billing Code Overview
HCPCS Level II code J1060 represents an injection formulation containing testosterone cypionate and estradiol cypionate, up to 1 ml. This code is used for billing a combined injectable hormone preparation that delivers both an androgen and an estrogen in a single-dose formulation.
Service Type: Hormone therapy injection
Typical Site of Service: Outpatient clinic, physician office, or ambulatory injection center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a transgender woman or a cisgender female patient receiving hormone therapy requiring intramuscular combined testosterone cypionate and estradiol cypionate injection. The patient arrives at an outpatient infusion clinic or an ambulatory care office for a scheduled intramuscular injection. The clinical workflow includes verification of identity and consent, review of the current medication regimen and relevant labs (serum testosterone, estradiol, hematocrit), assessment for contraindications (active thromboembolic disease, uncontrolled hypertension), preparation of the medication (aseptic technique, dose verification), administration via intramuscular route (usually gluteal or deltoid), post-injection observation for immediate adverse effects, documentation of lot number and expiration, and scheduling of the next dose or follow-up visit. Typical sites of service are an outpatient clinic, ambulatory surgery center for supervised injections, or physician office where injectable hormone therapy is administered under direct supervision.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed and documented on the same day as the injection and is above-and-beyond the typical pre-procedure work. |
| 59 | Distinct procedural service | Use when the injection is reported with another procedure on the same day and the service is distinct and separate.